Profile data is unavailable for this security.
About the company
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
- Revenue in USD (TTM)10.00k
- Net income in USD-37.28m
- Incorporated2003
- Employees35.00
- LocationGlycoMimetics Inc9708 Medical Center DriveROCKVILLE 20850United StatesUSA
- Phone+1 (240) 243-1201
- Fax+1 (240) 243-1018
- Websitehttps://glycomimetics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trinity Biotech plc (ADR) | 56.83m | -36.87m | 16.09m | 380.00 | -- | -- | -- | 0.2831 | -4.82 | -3.14 | 7.42 | -15.67 | 0.7501 | 1.76 | 3.83 | 149,557.90 | -48.66 | -20.30 | -61.88 | -29.54 | 34.22 | 39.92 | -64.87 | -29.86 | 1.27 | -1.61 | 1.55 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
| Traws Pharma Inc | 226.00k | -18.95m | 16.33m | 16.00 | -- | 1.27 | -- | 72.28 | -0.9029 | -0.9029 | 0.0108 | 0.5081 | 0.0073 | -- | 9.62 | 14,125.00 | -61.07 | -63.43 | -84.61 | -85.72 | -- | -- | -8,384.07 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 16.71m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| Senti Biosciences Inc | 2.56m | -92.72m | 16.88m | 48.00 | -- | 0.252 | -- | 6.59 | -2.09 | -1.60 | 0.0577 | 1.46 | 0.0171 | -- | 6.94 | 53,354.17 | -61.76 | -- | -68.80 | -- | -- | -- | -3,620.54 | -- | -- | -- | 0.0015 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
| Nascent Biotech Inc | 0.00 | -2.09m | 16.94m | -- | -- | 554.47 | -- | -- | -0.0147 | -0.0147 | 0.00 | 0.0002 | 0.00 | -- | -- | -- | -346.80 | -815.53 | -- | -- | -- | -- | -- | -548.75 | -- | -- | 0.8045 | -- | -100.00 | -- | -495.46 | -- | -- | -- |
| Talis Biomedical Corp | 2.13m | -62.01m | 16.94m | 99.00 | -- | 0.2452 | -- | 7.94 | -34.26 | -34.26 | 1.18 | 37.93 | 0.0162 | -- | 11.92 | 21,555.55 | -46.98 | -68.18 | -51.14 | -74.22 | 98.08 | -- | -2,905.67 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Plus Therapeutics Inc (USA) | 4.91m | -13.32m | 16.99m | 20.00 | -- | -- | -- | 3.46 | -4.51 | -4.51 | 1.57 | -0.3033 | 0.2787 | -- | -- | 245,650.00 | -75.54 | -59.18 | -210.10 | -133.04 | -- | -- | -271.04 | -470.45 | -- | -- | 1.51 | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| GlycoMimetics Inc | 10.00k | -37.28m | 17.18m | 35.00 | -- | -- | -- | 1,718.25 | -0.5791 | -0.5791 | 0.0002 | -- | 0.0002 | -- | -- | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Talphera Inc | 651.00k | -10.29m | 17.25m | 15.00 | -- | 1.22 | -- | 26.49 | -0.7287 | -1.47 | 0.0457 | 0.832 | 0.0192 | -- | -- | 43,400.00 | -30.31 | -22.60 | -41.48 | -28.55 | -- | -- | -1,580.18 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 17.52m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Flora Growth Corp | 76.07m | -47.36m | 17.56m | 97.00 | -- | 1.91 | -- | 0.2309 | -6.62 | -7.97 | 10.04 | 0.7167 | 1.45 | 6.76 | 31.13 | 784,237.10 | -89.22 | -- | -130.91 | -- | 23.32 | -- | -61.35 | -- | 0.7897 | -- | 0.2317 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
| Cocrystal Pharma Inc | 0.00 | -17.98m | 17.59m | 12.00 | -- | 0.6668 | -- | -- | -1.90 | -1.90 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -49.89 | -50.94 | -53.19 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| VBI Vaccines Inc | 8.68m | -93.84m | 17.78m | 131.00 | -- | 1.97 | -- | 2.05 | -9.42 | -9.42 | 0.5588 | 0.3147 | 0.0717 | 1.66 | 184.72 | 66,274.81 | -76.71 | -46.58 | -143.53 | -58.62 | -44.09 | -277.46 | -1,069.29 | -2,755.98 | 0.3662 | -4.28 | 0.8709 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
| Aytu Biopharma Inc | 98.50m | -18.00m | 18.21m | 150.00 | -- | 0.5541 | -- | 0.1848 | -4.06 | -4.06 | 20.97 | 5.90 | 0.7224 | 2.79 | 3.59 | 656,653.30 | -13.20 | -33.56 | -25.46 | -52.81 | 63.24 | 56.89 | -18.27 | -73.81 | 0.9094 | -0.4382 | 0.3281 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -14.82m | 18.22m | 2.00 | -- | 0.5853 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
Data as of May 10 2024. Currency figures normalised to GlycoMimetics Inc's reporting currency: US Dollar USD
44.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 15 Mar 2024 | 9.54m | 14.82% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 8.59m | 13.34% |
| Octagon Capital Advisors LPas of 31 Dec 2023 | 3.00m | 4.66% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.75m | 4.27% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2023 | 1.59m | 2.47% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 919.36k | 1.43% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 715.89k | 1.11% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 510.91k | 0.79% |
| Geode Capital Management LLCas of 31 Dec 2023 | 478.88k | 0.74% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 330.53k | 0.51% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
